Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-002511
Filing Date
2025-04-14
Accepted
2025-04-14 09:05:53
Documents
38
Period of Report
2025-02-28

Document Format Files

Seq Description Document Type Size
1 10-Q cnbx_i10q-022825.htm   iXBRL 10-Q 401788
2 CERTIFICATION cnbx_3101.htm EX-31.1 9992
3 CERTIFICATION cnbx_3102.htm EX-31.2 10074
4 CERTIFICATION cnbx_3201.htm EX-32.1 4879
5 CERTIFICATION cnbx_3202.htm EX-32.2 4776
  Complete submission text file 0001683168-25-002511.txt   2072530

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20250228.xsd EX-101.SCH 15336
7 XBRL CALCULATION FILE cnbx-20250228_cal.xml EX-101.CAL 26232
8 XBRL DEFINITION FILE cnbx-20250228_def.xml EX-101.DEF 36302
9 XBRL LABEL FILE cnbx-20250228_lab.xml EX-101.LAB 179113
10 XBRL PRESENTATION FILE cnbx-20250228_pre.xml EX-101.PRE 136501
41 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q-022825_htm.xml XML 169484
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

EIN.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 25834335
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)